It will benefit states by lowering their drug spending. But that's going to be very difficult in terms of the revenue hit to companies. In many cases, The difference between the MFN price and the prices paid in Medicaid could be substantial for some single source drugs. source drugs ultimately. And you know, my final point here would be I think we need to move towards some type of tiered pricing globally where you basically price drugs … (01:53–02:06)
CLAIM
Asserts that there could be a substantial difference between MFN and Medicaid prices for some drugs.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
